Veeco launches Lumina+ MOCVD system, receives Rocket Lab order
SAN JOSE & TEMPE - Align Technology, Inc. (NASDAQ:ALGN) has filed a complaint with the U.S. International Trade Commission (ITC) against Angelalign Technology, Inc., alleging unauthorized importation and sale of clear aligners that infringe on Align’s patents.
The complaint, filed under Section 337 of the Tariff Act, seeks an exclusion order to prevent importation of the allegedly infringing products into the United States and a cease-and-desist order to stop sales of such products already in the U.S. market.
This legal action is part of a broader intellectual property dispute between the companies. In August, Align initiated patent infringement litigation against Angelalign in the U.S. District Court, China Intermediate People’s Court, and European Unified Patent Court.
"We are taking the necessary steps through the ITC to protect our patented technologies and significant R&D investments from unlawful importation and use," said Julie Coletti, Executive Vice President and Chief Legal and Regulatory Officer at Align Technology.
Align Technology is known for its Invisalign System of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
The company claims to have treated over 20.8 million patients with the Invisalign System during its 28-year history.
The information in this article is based on a press release statement from Align Technology.
In other recent news, Align Technology has been the focus of several analyst updates and corporate developments. Piper Sandler has reiterated an Overweight rating with a $190 price target, emphasizing the company’s ongoing patent infringement litigation against competitor Angel across the United States, Europe, and China. Stifel has maintained a Buy rating and a $200 price target, highlighting Align Technology’s new pricing strategies aimed at increasing its market share among teenagers and reducing provider defections. Meanwhile, Mizuho has adjusted its price target to $210 from $245, citing weaker patient conversion trends as a concern, despite a positive analyst meeting in May 2025. Additionally, Align Technology announced the termination of Stuart Hockridge, Executive Vice President of Global Human Resources, effective May 2026, with severance terms aligned with his employment agreement. These recent developments reflect Align Technology’s strategic moves and ongoing challenges in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.